Board of Directors
President and CEO, Board Director
Karen has more than 25 years’ experience in the life sciences and medical device industry. She managed the body contouring franchise at Cynosure, directing marketing and product management of several aesthetic product lines for treatment of cellulite and fat reduction. She has a track record of launching exceptionally successful products and building commercial teams while spearheading operational improvements to drive productivity and increase value for the company. Previously, Karen was Head of Marketing for the Lab Solutions business at EMD Millipore. Through her 12 year tenure at EMD Millipore she successfully developed many new technologies, held various roles such as marketing manager, research and development scientist, and quality manager. She began her career in the biotech industry working with TransKaryotic Therapies. Karen has a B.S. in Microbiology from the University of New Hampshire and earned an M.B.A. with honors from Northeastern University.
Chief Financial Officer
Diane has provided financial and strategic advisory services to a number of venture-backed technology and life sciences companies, including Fractyl Laboratories Inc., T2 Biosystems, TARIS Biomedical, ByAllAccounts, Inc., Ivenix and Topera Medical. For more than 20 years working across private and public sector organizations, she has consistently built effective teams, strengthened relationships with investors, partners, customers and employees, and secured funding and negotiated critical business agreements. Previously, she was Chief Financial Officer and VP of Finance and Administration for Incentive Systems (dba Centive), a privately held venture-funded software company, and Chief Financial Officer at Workgroup Technology, a publicly traded software company with domestic and international operations. Diane earned her CPA at PricewaterhouseCoopers, formerly Coopers & Lybrand, and a BS in Business Administration from Boston College.
SVP Quality, Regulatory and Clinical
Tracey brings a wealth of expertise and experience successfully implementing and maintaining quality and regulatory systems and managing global clinical trials in a diverse range of environments, from start-up enterprises to Fortune 500 companies. She has a proven ability to build and manage compliant systems including product development, design control and business compliance programs. Tracey has held executive management positions at Abbott Laboratories, STERIS, Insulet Corporation, Dx Tech, Oscient Pharmaceuticals and ElectroSonics Medical. She also established her own consulting company, Qualtra Consulting Inc., providing Clinical, Regulatory and Quality System services to the medical device industry. Most recently, Tracey was the Vice President of Regulatory Affairs and Quality Assurance at OMNI LifeScience. Tracey holds an M.S. in Health Product Regulation, B.A. in Interdisciplinary Studies from the University of Toledo and Regulatory Affairs Certification.
SVP R&D and Operations
Steve has over 20 years of experience designing, developing and commercializing medical devices. He brings to Cytrellis a proven track record of success in multiple technical leadership roles, with a strong focus on devices with embedded software and electronics. Steve was most recently VP of Operations Excellence at Onduo, a healthcare start-up. He also spent several years as a VP of R&D at Insulet Corporation, where he led product development and sustaining engineering activities for Insulet’s insulin management and drug delivery systems. He has broad experience in program management and leading operations improvement programs, scaling organizations for product launch and optimizing for post-launch success. Steve has Masters degrees from Worcester Polytechnic Institute (Biomedical Engineering & Computer Science) and a BS in Mechanical Engineering from Tufts University.
Cathleen joins Cytrellis with extensive experience developing and executing product management and marketing strategies for medical device companies. Prior to Cytrellis, Cathleen worked as Executive Director of Global Product Marketing at Cynosure where she led both the aesthetic and body contouring franchises responsible for a wide variety of laser applications including skin revitalization, tattoo and non-invasive fat removal. Cathleen played a key role in launching many of the company’s most successful global products including Revlite SI, PicoSure and SculpSure. Before joining Cytrellis, she held leadership positions at PTS Diagnostics, GE Healthcare and RCI. Cathleen began her career in sales, earning multiple awards for outstanding performance. She has a B.A. in Chemistry and Communications from Denison University.
Chairman of the Board
John McDonough is President and Chief Executive Officer of T2 Biosystems and has been a member of T2 Biosystem’s Board of Directors since November 2007. From 2003 to 2007, John held various positions at Cytyc Corporation, a company engaged in the design, development, manufacturing and marketing of clinical products that focus on women’s health, and ultimately served as President at Cytyc Development Corporation. John had the responsibility of designing and executing Cytyc Corporation’s growth strategy for expanding the company from a single product company with revenue of approximately $300 million to a diverse women’s health company with revenue of approximately $750 million. He led the efforts that resulted in Cytyc’s acquisition by Hologic, Inc. in October, 2007, for over $6 billion. He has served in senior executive management and CEO roles in several private and public companies. He is currently also a member of the Board of Directors at Solace Therapeutics. Mr. McDonough earned his B.S.B.A. from Stonehill College.
Keith L. Crandell
Keith Crandell is a Managing Director and Co-Founder of ARCH Venture Partners, L.P., a global seed and early stage venture capital firm focused on innovations in the life and physical sciences.. Keith holds an M.B.A. from The University of Chicago (Booth), an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.
Mike has been involved in the R&D and Product Development process for over 35 years, playing key roles in the introduction of innovative products. With Merz since 2014, he currently serves as VP, Chief Technology Officer for the Merz Device Innovation Center. He was the Vice President of R&D at Ulthera, Inc. before it was acquired by Merz in 2014. Mike has spent the last 17 years in the medical device space after leading R&D, Product Development and Project Management functions in a variety of industries including aerospace, semi-conductor and retail products. He was the VP of R&D when Select Comfort (AIRB) went public in 1998 and has been recognized as a “Distinguished Corporate Inventor” by the American Society of Patent Holders due to his product patents in multiple industries. Mike holds a Bachelor of Science in Aerospace & Mechanics from the University of Minnesota.
Frederick Beddingfield III, MD, PhD
Frederick C. Beddingfield III, MD, PhD is Founder, President and CEO of Sienna Biopharmaceuticals. He is also a board-certified dermatologist and dermatologic surgeon. Dr. Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals, Inc. from March, 2013 until it was acquired by Allergan in October, 2015. Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield also served as Chief Medical Officer of Allergan Medical and led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, LATISSE®, and NATRELLE® Breast Implants. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, psoriasis, rosacea, scarring, hyperhidrosis, and hair loss.
Dr. Beddingfield earned an MD degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies, while simultaneously completing his Dermatology residency and Dermatologic Surgery fellowship at UCLA in the STAR program. He was the recipient of the Elle Genius Award in 2009. Currently, Dr. Beddingfield is a Clinical Associate Professor of Medicine/Dermatology at the UCLA School of Medicine where he has been on the faculty teaching and seeing patients since 2003. He serves on the Board of Directors of Advancing Innovation in Dermatology and is a founder of the Dermatology Summit and Dermatology Entrepreneurship Conferences.
Fred Aslan, MD
Fred Aslan is President and Chief Business Officer of Vividion Therapeutics, a San Diego-based biotech company. Fred is also Founder and Executive Chairman of Adavium Medical (holding company of Vydence Medical and previously Vyttra Diagnosticos). Vydence Medical has grown to become one of the leading Brazilian aesthetic device companies with a proprietary line of energy-based devices sold globally and as distributor for several international aesthetic devices. While CEO of Adavium Medical, Fred had the opportunity to launch and commercialize in Brazil a number of premier aesthetic device brands including CoolSculpting® and ARTAS®. Prior to Adavium Medical, Fred was an investor at Venrock where he led investments in Zeltiq, an aesthetic device company subsequently acquired by Allergan, and in PowerVision, an ophthalmology device company subsequently acquired by Alcon. While at Venrock, Fred also co-founded and served as board member of Receptos Pharmaceuticals, a biotech company subsequently acquired by Celgene. Earlier in his career Fred was Director of Business Development at CuraGen, a genomics company, and a management consultant at Boston Consulting Group (BCG). Fred also serves on the Board of Directors of Femasys, a women’s health medical device company. Fred has a B.S. in Biology from Duke University, an M.D. from Yale School of Medicine, and an M.B.A. from Harvard Business School.
Rox Anderson, MD
Founder, Medical / Technology Advisor
Dr. Anderson practices dermatology at Massachusetts General Hospital and teaches at Harvard and MIT and serves on many clinical advisory boards and industry committees. He has conceived and developed many of the ground breaking laser treatments now widely used in medical care. He co-invented fractional laser treatment, and recently developed a new strategy for epidermal grafting of wounds. His research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions. Dr. Anderson graduated from MIT, and then received his MD degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology. After completing his dermatology residency and an NIH research fellowship at Harvard, he joined the faculty where he is now Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine; and adjunct Professor of Health Sciences and Technology at MIT. Dr. Anderson has been awarded over 60 national and international patents, and has co-authored over 250 scientific books and papers.
William G. Austen, Jr. MD
Founder, Medical / Technology Advisor
Dr. Austen is the Chief of the Division of Plastic & Reconstructive Surgery and Chief of the Division of Burn Surgery at the Massachusetts General Hospital, Harvard Medical School. His laboratory focuses on translational research in the field of plastic and reconstructive surgery, with an emphasis on moving novel concepts in the field from the bench top to the bedside. Dr. Austen is a member of numerous societies including the Society of University Surgeons, the American College of Surgeons, the American Association of Plastic Surgeons, and the American Society of Plastic Surgeons. He has won numerous awards including the Best Paper of the Year in Plastics & Reconstructive Surgery 2015 and Teacher of the Year in Plastic Surgery at Harvard Medical School. Dr. Austen received his undergraduate degree at Princeton followed by his medical degree at Harvard Medical School and trained in General Surgery and Plastic Surgery at Harvard Medical School followed by a Fellowship in Craniofacial Surgery at the Royal Children’s Hospital in Melbourne, Australia.
Doug Levinson, PhD
Doug Levinson is a serial entrepreneur who has created and led numerous successful companies in the life sciences. Prior to Cytrellis, Doug was a Partner at Flagship Ventures where he co-founded and served as CEO of T2 Biosystems (TTOO) and Seventh Sense Biosystems. Doug was a member of the founding team of TransForm Pharmaceuticals and served as a member of the Management Team from the company’s initial founding through its acquisition by J&J in 2006. At TransForm, he served as Vice President of Emerging Science and Technology where he led the design, development and implementation of TransForm’s basic technology platforms and business model. Prior to TransForm, Doug was at Millennium Pharmaceuticals for 7 years, which he joined as a founding scientific team member and was responsible for establishing the company’s early scientific program in Immunology/Inflammation. Doug holds a Ph.D. in Genetics from Harvard University and a B.S. cum laude in Molecular Biology from the University of Massachusetts. He has authored numerous patents in the field of high throughput platform technologies and molecular genetics and has published extensively in scientific journals. He currently serves as the University of Virginia Biomedical Engineering Department’s Coulter Translational Partnership Oversight Committee and is a faculty member of the MIT IMPACT Program.